Clinical Trial

Company news: Auxilium and GSK; J&J's Janssen

May 22, 2012

Auxilium inked a co-promote deal with GSK on its Testim 1% testosterone gel for the US.
 

An FDA denial, but not the last word on Merck combo lipid drug

March 06, 2012

An experimental lipid-lowering combo drug developed by Merck hit a snag, but its real test is yet to come, says one analyst.
 

Setback, not disaster, for Gilead hep. C regimen, analysts say

February 21, 2012

In the race to develop an all-oral hepatitis C therapy, Gilead Sciences just saw its lead shrink.
 

New indication may give Xarelto a sales boost

October 04, 2011

Will Xarelto become the first Factor Xa inhibitor with an indication for use in patients who have had a heart attack or similar symptoms?
 

Eliquis stacks up better than Pradaxa or Xarelto

August 30, 2011

Eliquis has demonstrated, in convincing fashion, that it's superior in efficacy and bleeding profile to standard warfarin therapy, and neither Pradaxa nor Xarelto can match it in overall mortality or safety.
 

Results of heart study bring Bydureon back from brink, analyst says

July 08, 2011

The results, showing the long-acting diabetes med had passed a crucial test of its effects on heart rhythms, put the drug back on track after a spate of regulatory delays, wrote one analyst.
 

Merck scales back vorapaxar trials

January 13, 2011

Merck said it's stopping one of two big clinical trials of an experimental blood thinner that some viewed as the firm's highest profile pipeline drug.
 

Results may help Merck expand use of Vytorin

November 23, 2010

Based on positive results of Vytorin (ezetimibe/simvastatin) in patients with chronic kidney disease (CKD), Merck said it will apply for use of the cholesterol-lowering drug in this population.
 

Specialty societies' code targets conflicts of interest

April 22, 2010

Medical society journals must ban ghostwritten articles and cannot place ads for drugs next to editorial content discussing those products or their makers under a sweeping ethics code signed by several major medical societies.
 

Pfizer physician payments totaled $35m for second half of '09

March 31, 2010

Pfizer paid out $35 million to 4,500 healthcare professionals in the second half of 2009, the company reported.
 

Abbott's next step for Niaspan

January 05, 2010

Abbott Labs' cholesterol drug Niaspan is growing prescription share nicely after a clinical trial highlighted its potential as part of a one-two punch in reducing plaque. Now, the company says, it is considering how best to capitalize on the data.
 

ARBITER leaves some lasting marks on Merck

December 21, 2009

The nature and amount of press coverage is often a key factor in assessing how clinical trial results impact a product's prescription trends. In the case of the ARBITER 6-HALTS trial, Merck's cholesterol franchise has benefited from largely balanced coverage, somewhat limiting damage to lipid drugs Zetia and Vytorin.
 

Pfizer clinical trials portal stresses privacy

August 19, 2009

Pfizer is launching an "online community" designed to speed clinical trials recruitment while safeguarding patient privacy rights.
 

GSK to expand clinical trial disclosures

March 26, 2009

GlaxoSmithKline said it will broaden its transparency policies to include greater disclosure of its clinical research and the physicians the company works with on clinical trials.
 

Iowa Senate passes harsh gifts, data ban bill

March 20, 2009

Iowa's state Senate passed a healthcare bill containing some of the toughest restrictions on drug company contacts with physicians yet.
 

MedPAC calls for reporting of samples

March 03, 2009

An influential advisory board urged Congress to impose far-reaching transparency rules on payments to healthcare professionals and organizations interacting with the drug industry--including reporting samples, in part to aid counterdetailing efforts.
 

Medtronic vows public disclosure of payments to docs

February 24, 2009

Medtronic said it will disclose payments to US physicians starting in 2011.
 

Pfizer aborts investigational compounds, reprioritizes

February 24, 2009

Pfizer terminated phase 3 development on two investigational compounds today after halting trials on axitinib, a phase 3 pancreatic cancer treatment, in January.
 

Pfizer hops on transparency bandwagon with disclosures

February 09, 2009

Following the lead of peers like Lilly and GSK, Pfizer announced plans to publicly disclose payments to US physicians, healthcare professionals and clinical investigators in excess of $500 per year, along with non-monetary items worth more than $25.
 

Sunshine bill is back with sharper teeth

January 22, 2009

Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) reintroduced their Physician Payments Sunshine Act, which would require that manufacturers and group purchasing organizations disclose payments to physicians of $100 or more.
 

Grassley questions Prempro ghostwriting practices

December 12, 2008

Sen. Chuck Grassley (R-IA) today sent letters to Wyeth and a third party regarding Prempro-related journal articles, and specifically the use of ghostwriters, the New York Times reported.
 

Lilly settlement with states demands even greater transparency

October 09, 2008

Eli Lilly & Co.'s $62 million settlement with 32 states and the District of Columbia over off-label Zyprexa marketing comes with an agreement requiring, among other things, that the company furnish those state AGs with a list of all healthcare professionals paid more than $100 for promotional speaking and consulting in the US.
 

Vioxx trial described as marketing stunt

August 20, 2008

Researches involved in the litigation against Vioxx claim the product's ADVANTAGE trials were based on marketing objectives rather than scientific rigor.
 

New York governor wants gift ban

May 22, 2008

New York Gov. David Paterson is proposing legislation that would impose a ban on gifts to doctors and require physicians making presentations at CME events to disclose any financial relationships with drug companies.
 

Wyeth, Elan halt study of Alzheimer's vaccine

April 18, 2008

Wyeth and Elan have suspended a clinical study of their jointly developed Alzheimer's vaccine ACC-001 after a patient receiving the treatment was hospitalized for nearly two weeks with skin ulcers.
 

Crestor to benefit as ENHANCE smoke clears: survey

April 10, 2008

Expect AstraZeneca's Crestor to emerge as the big winner in the aftermath of Merck/Schering Plough's Vytorin debacle, primary care physicians (PCPs) said.
 

Georgia Tech researchers aim to improve trials outcomes, boost Rx compliance with sensor necklace

March 07, 2008

Researchers from the Georgia Institute of Technology (GIT) have devised an innovative medication monitoring device that could prove to be a useful tool for pharma researchers and marketers of the future.
 

GSK avoids UK prosecution over antidepressant clinical trials data

March 06, 2008

The UK's drugs regulatory agency said it would not prosecute GlaxoSmithKline (GSK) for allegedly withholding clinical trials data related to its antidepressant Seroxat (paroxetine), sold in the US under the brand name Paxil.
 

Study claims antidepressants benefit only small portion of patients

February 27, 2008

A new study of prescription antidepressants published this week suggests the drugs may be no more effective than placebo in treating the most common forms of depression.
 

Schering-Plough posts Q4 loss as Congress eyes web posts in Vytorin probe

February 12, 2008

Schering-Plough posted a fourth quarter loss on charges related to its acquisition of Organon and said it was ready to take action if sales of Vytorin and Zetia decline significantly.
 

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
 

MM&M Awards 2011 HIghlights

The Best MM&M Awards Ever!

MAHF Ceremony 2012

Photos from the Medical Advertising Hall of Fame Awards ceremony
 
Popular Topics
Acquisition Adherence App Celebrity Clinical Trial Co-Marketing Conflict Of Interest Diabetes Diagnostics Digital Direct To Consumer (DTC) Disease Awareness Downsize Education & Awareness FDA Government Guidance Health Plans HMOs Hospitals Insurers Law Marketing Research Mobile Sales Force